Introduction
============

With the world's aging population on the rise, and an increasing prevalence of Alzheimer's disease (AD), dementia has become an important area for global research. Mild cognitive impairment (MCI) is defined as a cognitive disorder associated with deficits in memory, language, executive functioning, attention, and visual-spatial abilities. In Shanghai, China, the prevalence of adult MCI (aMCI) in people aged 60 years and older is 22.3%.[@b1-cia-13-1313] Research in other cities in China or USA has found a similar prevalence rate.[@b2-cia-13-1313]--[@b4-cia-13-1313] A retrospective cohort study found that the progression from MCI to dementia or AD was \~13.5%--13.9% person-years.[@b5-cia-13-1313] The identification and treatment of those at high risk for developing dementia are therefore critical.

The benefits of nonpharmaceutical interventions in older adults with cognitive impairment have been widely reported.[@b6-cia-13-1313] However, a systematic review by Zubala et al[@b7-cia-13-1313] states that the component of cognitive interventions providing the greatest benefits in older adults is still unclear. Prior research has provided evidence that consistent physical training[@b8-cia-13-1313],[@b9-cia-13-1313] and social activities may maintain neuronal plasticity and increase brain activity in older adults.[@b10-cia-13-1313] Physical exercise has been shown to increase the number of neuronal and non-neuronal cortical cells and hippocampal neuronal cells in adolescent rats.[@b11-cia-13-1313] Other research has shown that specific activities, such as playing sports or an instrument, specifically the drums, provide long-term neuronal adaptation mechanisms and increase visual-spatial abilities.[@b12-cia-13-1313] In addition, animal studies have shown that spatial memory tasks may benefit memory over a 4-month period.[@b13-cia-13-1313]

Social behavioral activation (SBA) has been shown to slow cognitive decline in people with MCI or at risk for dementia.[@b14-cia-13-1313] SBA involves components of strength, frequency, duration, and patterns, which have been seen in traditional health care programs. Moreover, tasks involving memory, such as strategy training (creating a weekly plan) and a daily schedule (reading newspaper and sharing to audience) that enhance motivation and demand integration of multiple cognitive pathways, can also lead to a slowing of cognitive decline.[@b15-cia-13-1313]

Novel cognitive intervention programs such as Timeslips build upon art therapy and humanities. The storytelling program has been reported in several previous studies,[@b16-cia-13-1313] and it has been suggested that the engaging nature of this group-centered activity may specifically benefit patients emotionally and improve communication skills and memory in older adults with AD or dementia. The details of this creative expression (CrExp) program have been reported in previous publications.[@b17-cia-13-1313],[@b18-cia-13-1313] Briefly, storytelling is used to strengthen memory in elderly patients with MCI. The CrExp program involves five steps of functional tasks related to the presentation of a picture, including the topic of the picture, the background scenery, the development of a story, the actions of the leading character, and the ending of the story. Symbols, graphs, lines, numbers, and colors can be used to express feelings or emotions in order to narrate a vivid and complete story during the task. The CrExp program is conducted in a group setting.

The "dual-coding theory" of cognition emphasizes that both visual and verbal data are used in memory tasks. This theory suggests that there are two distinct channels for the organization of incoming messages that can be acted upon, stored, and retrieved for subsequent use.[@b19-cia-13-1313] While prior research has shown that storytelling-based CrExp training exerts a positive influence on older adults with AD, whether it can be used as an effective tool in treating elders with MCI or cognitive disorders at risk of dementia remains unclear. The current study explored the effects of a CrExp training program on cognitive functioning in older adults with MCI. In addition to storytelling, drawing tasks were used as an exercise demanding visual imagery to stimulate parallel cognitive processes and artistic expression.

Methods
=======

Study design
------------

The current study was a 16-week cluster-randomized clinical trial conducted from January 2015 to March 2016 at the outpatient clinic at the Fujian Provincial Hospital. Participants were randomly assigned to either the CrExp group or a control group (CG) who received social activation therapy by computer-generated random numbers. Cluster randomization was carried out by a statistician after screening was completed. Group assignment was concealed until the completion of baseline assessment. The assessor was not involved in the intervention, and the interventionists were not involved in the outcome assessments.

Each participant provided written informed consent, and all procedures were approved by the hospital ethics committee. The study was conducted according to the Declaration of Helsinki and was registered in the Chinese Clinical Trials Registry (trial registration number: ChiCTR-ONN-16007776).

Participants
------------

Adults aged 60 years or older from the Department of Geriatrics or Neurology at a public tertiary A hospital who complained of memory issues or had suspected cognitive impairment were examined. A total of 93 patients met the following inclusion criteria for MCI:[@b20-cia-13-1313] memory/cognitive complaint reported by the patient or a caregiver within past year; clinical record of probable MCI according to the *Diagnostic and Statistical Manual of Mental Disorders, 4th Edition* (DSM-IV); objective cognitive impairment in one or more domains as revealed by neuropsychological assessments; and normal personal self-care and daily living ability. The exclusion criteria were as follows: known psychiatric cause of cognitive dysfunction; clinical diagnosis of depression or anxiety; history of brain lesion; psychoactive substance abuse; comorbid medical records associated with cognitive functional decline; and taking medications with significant impacts on cognitive function or influence on hearing, vision, or communication that may affect participation in the program or assessments.

Measurements
------------

Assessments were made by a professional cognitive assessor at baseline, postintervention, and 6 months follow-up. Primary outcomes were the Chinese-Changsha version of Montreal Cognitive Assessment (MoCA),[@b21-cia-13-1313] the Chinese Version of the Auditory Verbal Learning Test (CVAVLT),[@b22-cia-13-1313] the Chinese Version of the Category Verbal Fluency Test (CVCVFT),[@b23-cia-13-1313] the Digital Span Test (DST),[@b24-cia-13-1313] the Chinese version of the Trail Making Test A (TMT-A) and the Trail Making Test B (TMT-B),[@b25-cia-13-1313] and the Chinese Version of Activities of Daily Living scale (CVADL).[@b26-cia-13-1313] The above-mentioned scales were used to test the general cognitive function including memory, language, executive, attention, and spatial ability. The Memory Satisfaction Questionnaire (MSQ) was developed to evaluate the affect regarding one's memory by adding up the score of 20 items using a 4-point (0--4) Likert scale.[@b27-cia-13-1313] More information can be found from the reference cited.

Intervention
------------

### CrExp group

The cognitive program for the CrExp group involved a total of 25 sessions over 16 weeks, facilitated by a group of professional therapists. All sessions began with a 5--10 min warm-up of an interaction game, followed by a 10 min drawing and then a 30 min core CrExp. Session ended with a 5--10 min discussion and a 5 min conclusion.

### CG

The CG participated in standard cognitive rehabilitation, which involved a total of the same sessions as CrExp group over 16 weeks, facilitated by a group of occupational therapists (social workers, nursing specialists, and physicians). Each session included 10 min of "finger exercises",[@b28-cia-13-1313] followed by 30 min of core cognitive strategy training (eg, a course, an activity, or a game) and, finally, 5 min of conclusion speeches.

Throughout the study, all participants continued with their routine medical care and out-patient follow-up.

Statistical analysis
--------------------

All analyses were performed using STATA 12.0 (StataCorp LP, College Station, TX, USA).[@b29-cia-13-1313] Group differences in demographics and baseline assessments were compared using the appropriate statistical tests (Fisher's exact test, independent samples *t*-test, or chi-square test). The intervention effects, over time from baseline to postintervention and from baseline to 6 months follow-up, were evaluated using repeated measures of ANOVA. The between-group differences at postintervention and 6 months follow-up were performed by ANCOVA with baseline age, education, and MoCA score as covariates. Bonferroni analyses were performed when significant between-group differences were revealed. All data were analyzed according to the intention-to-treat principle. Missing data were replaced by averaging the individual's available data (from first session to last observation). The statistical significance level was set at *P*\<0.05 (two-tailed).

Results
=======

Participant characteristics
---------------------------

Of the 134 patients screened for eligibility, 41 patients met some exclusion criteria, 37 patients did not meet inclusion criteria, and four patients declined participation. Therefore, 93 individuals (50 males and 43 females), aged 60--85 years (mean =69.2, SD =6.3), were randomly assigned to either the CrExp group (n=48) or the CG (n=45). Baseline demographics and a study flow chart are provided in [Table 1](#t1-cia-13-1313){ref-type="table"} and [Figure 1](#f1-cia-13-1313){ref-type="fig"}, respectively. There were no significant statistical differences in characteristics (range *P*=0.253--0.987) or neuropsychological assessment results (range *P*=0.339--0.876) between the groups at baseline.

Compliance
----------

Of the 93 participants who completed the baseline assessment, 88 (94.6%) participants performed the postintervention evaluation and 84 (90.3%) participants completed the 6 months follow-up ([Figure 1](#f1-cia-13-1313){ref-type="fig"}). There were no significant differences between compliance and noncompliance participants at postintervention (*χ*^2^ \[1\]=0.876, *P*=0.349) or at 6 months follow-up (*χ*^2^ \[1\]=0.376, *P*=0.540). Adverse events were not reported from either group.

Effects of Intervention
-----------------------

All mean group assessment scores and between-group comparisons are illustrated in [Table 2](#t2-cia-13-1313){ref-type="table"}. The results of the repeated-measures ANOVA showed significant improvements in the CrExp group in all measurements at postintervention and at 6 months follow-up. Similarly, there was significant improvement in all assessments in the CG except activities of daily living (ADL) and complex social functioning.

At postintervention, the CrExp group showed significantly greater improvement than CG in general cognitive functions (MoCA; *F*=21.47, *P*\<0.001), memory (CVAVLT immediate recall; *F*=4.81, *P*=0.023 and delay recall; *F*=3.98, *P*=0.012), language function (CVCVFT; *F*=3.91, *P*=0.017), executive function (DST; *F*=23.35, *P*\<0.001), attention functioning (TMT-B; *F*=3.29, *P*=0.030), and memory satisfaction (MSQ; *F*=18.39, *P*\<0.001). When gender and ambulatory level were entered as covariates, there was also a significant difference between groups in ADL (CVADL; *F*=2.78, *P*=0.041).

Sustainability of effects
-------------------------

At 6 months follow-up, significant group differences remained in general cognitive functioning (MoCA; *F*=4.89, *P*=0.031), memory (CVAVLT delay recall; *F*=5.14, *P*=0.025), executive function (DST; *F*=4.35, *P*=0.034), attention functioning (TMT-B; *F*=6.19, *P*=0.016), ADL (CVADL; *F*=4.24, *P*=0.043), and memory satisfaction (MSQ; *F*=7.49, *P*=0.008).

Discussion
==========

The aim of this study was to compare the effectiveness of a CrExp training program with standard cognitive therapy in older adults with MCI at risk of dementia. The participants in the CrExp group showed greater improvements in general cognitive functioning, memory, executive functioning, attention, and ADL compared with the CG both at postintervention and at 6 months follow-up.

The results of the current study concur with previous studies showing that strengthening and demanding tasks, along with various behavioral exercises, lead to greater improvement in cognitive functioning than either treatment alone.[@b30-cia-13-1313],[@b31-cia-13-1313] While physical exercise and cognitive training were involved in the CG treatment, these interventions are likely practiced at home and, thus, did not provide further enhancement. The process of integrating professional resources and intensive training guidance, on the other hand, may increase cognitive motivation. However, there is a weak evidence for improvement in the domains of memory and executive function after short-term cognitive intervention for older adults with MCI and, as such, long-term intervention (as provided in the current study) may be critical.

Participants in the CrExp group showed significantly greater improvement than those in the CG, in general cognitive function, especially in executive functioning, language, and attention. These results strengthen the argument for the necessity of more frequent and longer sessions of CrExp programs in MCI patients. In addition, cognitive therapy should focus on consistent creative exercises involving imagination and narration.

While ADL was significantly improved at postintervention and at 6 months follow-up in the CrExp group, there was no significant improvement in CG. The ADL measures the degree of impairment in everyday basic functioning, evaluates the prognosis, and predicts daily functioning and motor performance in diseases associated with neurocognitive disorders or insufficient mental activity.[@b32-cia-13-1313],[@b33-cia-13-1313] ADL is intimately linked to working memory and executive and visuospatial functioning, which can be facilitated through sustained cognitive training.[@b34-cia-13-1313] The significant improvement in ADL performance in the CrExp group may be attributed to an enhancement in working memory through the practice of imaging, storytelling, and drawing exercises. More studies are needed to explore factors that correlate with improved ADL.

To our knowledge, the present study is the first to report on CrExp intervention in China. Patients with MCI may not present with significant neuropsychological deficits, but instead with mild cognitive dysfunction, especially in memory, speed, and accuracy, which have been associated with the normal aging process.[@b35-cia-13-1313] During CrExp exercises, MCI patients are given the opportunity to use creativity, imagination, and thinking processes that may otherwise remain used. In addition, those who participate in CrExp share stories with peers who may naturally stimulate improved communication, attention, and expression abilities as well as general cognition and well-being.

Limitations
-----------

While the present study provides evidence for the beneficial use of CrExp intervention in the elderly, there are limitations that warrant mentioning. First, the current study had a relatively small sample size that may not reliably represent MCI patients across clinical subtypes. In addition, participants were all residents of Fuzhou, China, and as such, the results may not generalize to other regions of China or other countries. Finally, due to limited human resources and short-term follow-up period, future studies should be designed to follow participants for at least 1 year postintervention.

Conclusion
==========

The current randomized controlled trial provides evidence that a CrExp program involving storytelling and picture-drawing tasks is effective in improving cognitive functioning and ADL in older adults at risk for dementia. In addition, the results suggest that cognitive improvements are sustained for at least 6 months postintervention. Health care providers should consider CrExp interventions as part of the treatment program for older adults with MCI.
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###### 

Baseline demographic and neuropsychological evaluations of participants

  Characteristics                                                 CrExp group (n=48)                     CG (n=45)                               *P*-value
  --------------------------------------------------------------- -------------------------------------- --------------------------------------- --------------------------------------------------
  Age (years), range/mean (SD)                                    60--85/70.6 (6.9)                      60--85/69.5 (6.7)                       0.816[a](#tfn1-cia-13-1313){ref-type="table-fn"}
  Gender, n (%), female/male                                      25 (52.1)/23 (47.9)                    23 (51.1)/22 (48.9)                     0.253[c](#tfn3-cia-13-1313){ref-type="table-fn"}
  Education level, n (%), illiterate/primary/secondary/tertiary   3 (6.2)/9 (18.8)/20 (41.7)/16 (33.3)   3 (6.7)/10 (22.2)/19 (42.2)/13 (28.9)   0.482[b](#tfn2-cia-13-1313){ref-type="table-fn"}
  Social status, n (%), living with family/alone                  47 (98.0)/1 (0.2)                      43 (95.6)/2 (4/4)                       0.503[c](#tfn3-cia-13-1313){ref-type="table-fn"}
  Exercise per day, n (%), 0/\<30 min/\>30 min                    9 (18.8)/16 (33.3)/23 (47.9)           10 (22.2)/14 (31.1)/21 (46.7)           0.968[b](#tfn2-cia-13-1313){ref-type="table-fn"}
  Ambulatory level, n (%), unaided/with stick                     45 (93.8)/3 (6.2)                      42 (93.3)/3 (6.7)                       0.417[c](#tfn3-cia-13-1313){ref-type="table-fn"}
  Medical history, n (%), hypertension/diabetes/dyslipidemia      16 (33.3)/24 (50.0)/8 (16.7)           15 (33.3)/22 (48.9)/8 (17.8)            0.987[b](#tfn2-cia-13-1313){ref-type="table-fn"}
  MoCA score, mean (SD)                                           22.04 (2.73)                           21.88 (2.96)                            0.339[a](#tfn1-cia-13-1313){ref-type="table-fn"}
  NCSE, composite score, mean (SD)                                50.87 (11.75)                          52.64 (12.03)                           0.890[a](#tfn1-cia-13-1313){ref-type="table-fn"}
  NCSE, normal domain, mean (SD)                                  4.87 (1.75)                            5.04 (2.13)                             0.277[a](#tfn1-cia-13-1313){ref-type="table-fn"}
  CVAVLT totally recall score, mean (SD)                          14.72 (3.47)                           15.03 (3.16)                            0.676[a](#tfn1-cia-13-1313){ref-type="table-fn"}
  CVAVLT delay recall score, mean (SD)                            5.72 (3.21)                            5.03 (3.16)                             0.676[a](#tfn1-cia-13-1313){ref-type="table-fn"}
  CVCVFT score, mean (SD)                                         10.18 (1.90)                           9.3 (2.35)                              0.351[a](#tfn1-cia-13-1313){ref-type="table-fn"}
  DST score mean (SD)                                             7.34 (1.28)                            7.45 (1.59)                             0.876[a](#tfn1-cia-13-1313){ref-type="table-fn"}
  TMT-A score mean (SD)                                           136.29 (31.31)                         132.14 (32.85)                          0.605[a](#tfn1-cia-13-1313){ref-type="table-fn"}
  TMT-B score mean (SD)                                           238.34 (12.99)                         245.14 (11.59)                          0.763[a](#tfn1-cia-13-1313){ref-type="table-fn"}
  CVADL score, mean (SD)                                          25.49 (2.39)                           26.06 (2.04)                            0.407[a](#tfn1-cia-13-1313){ref-type="table-fn"}
  MSQ score, mean (SD)                                            48.13 (0.84)                           47.26 (0.69)                            0.633[a](#tfn1-cia-13-1313){ref-type="table-fn"}

**Notes:**

Independent sample *t*-test.

Fisher's exact test.

Chi-square test.

**Abbreviations:** CG, control group; CrExp, creative expression; CVADL, Chinese Version of Activities of Daily Living; CVAVLT, Chinese Version of the Auditory Verbal Learning Test; CVCVFT, Chinese Version of the Category Verbal Fluency Test; DST, Digital Span Test; MoCA, Montreal Cognitive Assessment; MSQ, Memory Satisfaction Questionnaire; NCSE, Neurobehavioral Cognitive Status Examination; TMT-A, Trail Making Test A; TMT-B, Trail Making Test B.

###### 

Outcome at baseline, postintervention, and 3 months follow-up

  Measures           Groups, CrExp (n=48) and CG (n=45)   Baseline mean ± SE   Postintervention, mean ± SE   Follow-up mean ± SE   Postintervention   Follow-up                                                    
  ------------------ ------------------------------------ -------------------- ----------------------------- --------------------- ------------------ ----------- ------------------------ ----------- ----------- -------------------------
  MoCA               CrExp                                22.04±2.73           24.68±1.84                    24.33±1.53            0.001^\*^          \<0.001     *d*=0.79 (0.34, 1.43)    0.031^\*^   \<0.001     *d*=0.53 (0.10, 1.03)
  CG                 21.88±2.96                           23.13±1.68           23.07±1.20                                          \<0.001                                                 \<0.001                 
  NCSE               CrExp                                50.87±1.75           61.34±2.03                    60.90±1.84            \<0.001            \<0.001     *d*=0.82 (0.36, 1.36)    0.019^\*^   \<0.001     *d*=0.49 (0.07, 0.81)
  Normal domain      CG                                   52.64±1.03           57.33±1.15                    57.06±166                                0.001                                            \<0.001     
  NCSE               CrExp                                4.87±0.25            7.03±0.63                     7.16±0.86             0.001^\*^          \<0.001     *d*=0.86 (0.29, 1.31)    0.027^\*^   \<0.001     *d*=0.31 (−0.06, 0.70)
  Composite domain   CG                                   5.14±0.17            6.33±0.58                     5.92±0.75                                \<0.001                                          \<0.001     
  CVAVLT             CrExp                                5.72±0.41            7.48±0.67                     7.39±0.72             0.023^\*^          \<0.001     *d*=0.54 (0.08, 0.97)    0.145       \<0.001     *d*=0.67 (0.18, 1.13)
  Immediate recall   CG                                   5.03±0.36            6.35±0.59                     6.23±0.85                                \<0.001                                          \<0.001     
  CVAVLT             CrExp                                15.42±0.77           18.55±0.88                    19.70±0.94            0.026^\*^          \<0.001     *d*=0.43 (0.03, 0.89)    0.345       \<0.001     *d*=0.38 (−0.06, 0.75)
  Delay recall       CG                                   15.53±0.86           17.30±0.64                    18.16±0.73                               \<0.001                                          \<0.001     
  CVCVFT             CrExp                                9.81±0.69            11.77±0.58                    11.38±0.61            0.017^\*^          \<0.001     *d*=0.47 (0.05, 0.91)    0.109       \<0.001     *d*=0.51 (0.09, 0.88)
  CG                 9.77±0.58                            10.20±0.64           10.31±0.43                                          0.009^\*^                                               0.011^\*^               
  DST                CrExp                                7.34±1.28            9.63±1.28                     9.17±1.01             \<0.001            \<0.001     *d*=0.29 (−0.10, 0.75)   0.034^\*^   \<0.001     *d*=0.45 (0.03, 0.89)
  CG                 7.45±1.59                            8.69±1.48            7.44±1.43                                           0.013^\*^                                               0.021^\*^               
  TMT-A              CrExp                                136.29±11.13         113.40±8.61                   110.42±6.81           0.087              \<0.001     *d*=0.45 (0.01, 0.88)    0.089       \<0.001     *d*=0.63 (0.20, 1.04)
  CG                 132.14±12.85                         114.54±7.39          120.13±5.29                                         \<0.001                                                 \<0.001                 
  TMT-B              CrExp                                245.14±10.59         202.57±8.14                   198.91±7.90           0.030^\*^          \<0.001     *d*=0.38 (0.04, 0.76)    0.016^\*^   \<0.001     *d*=−0.11 (−0.55, 0.37)
  CG                 238.34±9.91                          215.45±7.51          221.77±8.57                                         \<0.001                                                 \<0.001                 
  CVADL              CrExp                                25.49±0.39           23.18±0.52                    23.11±0.32            0.041^\*^          0.002^\*^   *d*=0.92 (0.53, 1.46)    0.043^\*^   0.016^\*^   *d*=0.59 (0.16, 0.99)
  CG                 26.06±0.44                           25.49±0.47           25.21±0.36                                          0.063                                                   0.056                   
  MSQ                CrExp                                48.13±0.84           36.77±0.74                    37.54±0.59            \<0.001            \<0.001     *d*=0.66 (0.23, 1.06)    \<0.001     \<0.001     *d*=0.32 (−0.01, 0.69)
  CG                 47.26±0.69                           42.16±0.82           41.36±0.63                                          \<0.001                                                 \<0.001                 

**Notes:** Effect size was defined as Cohen's *d* of the CrExp group compared with the CG. Mean = adjusted mean after Bonferroni correction. ^\*^*P*\<0.05.

**Abbreviations:** CVADL, Chinese Version of Activities of Daily Living; CVAVLT, Chinese Version of the Auditory Verbal Learning Test; CVCVFT, Chinese Version of the Category Verbal Fluency Test; CG, control group; CI, confidence interval; CrExp, creative expression group; DST, Digital Span Test; MoCA, Montreal Cognitive Assessment; MSQ, Memory Satisfaction Questionnaire; NCSE, Neurobehavioral Cognitive Status Examination; SE, standard error; TMT-A, Trail Making Test A; TMT-B, Trail Making Test B.
